Biofrontera (B8F)

japp. bleibe an bord. 8)

evtl. eine kleine position verkaufen - man(n) will ja seiner strategie und prinzipien treu bleiben

Aurum wrote:

Heute im "Aktionär"

http://img163.imageshack.us/f/biofronteraderaktionr23.png/

sieht gut aus hier. beinahne wieder bei 3 Euro.

Quote:

03/31/2011 | 06:00 am

Biofrontera AG / Biofrontera publishes financial report 2010 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Highlights 2010:

Filing of marketing authorization application for BF-200 ALA and successful validation of the documents

Manufacturing and distribution license obtained

BF-200 ALA selected by Windhover as worldwide TOP-10 drug development project available for partnering

Distribution agreement for Belixos® in Arabic countries

Consolidation of Biofrontera shares under a single ISIN

Leverkusen, Germany - Biofrontera AG (DSE: B8F) today reports its financial results for the fiscal year 2010. The report, published today on the company's web site, illustrates the considerable progress in the product pipeline and provides an outlook for 2011.

"Important goals for 2010 included the filing of the marketing authorization application for BF-200 ALA and the strengthening of the market position of Belixos®. This was achieved and, in addition, we could financially secure Biofrontera through various capital measures", commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG.

Review of the fiscal year 2009

The annual loss was, with EUR 7.7 mln, in 2010 higher than in 2009 with EUR 3.4 mln. The increased loss was caused by positive one-time effects of the restructuring of the Biofrontera convertible bond 05/12 in 2009 and the accrual of EUR 1.5 mln for a purchase price in 2010. The payment was not yet executed due to disputable issues in the ordinary delivery and the settlement date. Revenues increased to TEUR 406 from TEUR 336 in 2009, which was due to increased sales of Belixos®, the diagnostic ViroSafe and components for pharmacy compounding.

With EUR 3.9 mln for research and development of Biofrontera group in 2010, the accounting was slightly higher than in 2009 (EUR 3.4 mln). Research and development expenses decreased continually since 2008 due to the completion of clinical trials, particularly the pivotal phase III trials of BF-200 ALA. The higher bookings in 2010 were due to the accrual of EUR 1.5 mln for the potential purchase price mentioned above, which was booked as research and development expense.

The capital flow from investment activities was with EUR 4.9 mln slightly higher than in 2009 (EUR 4.5 mln). These proceeds were mostly used to finance the completion of the development and the initiation of the drug approval process for BF-200 ALA.

At the end of the reporting year the free liquidity of Biofrontera AG was TEUR 692, compared to TEUR 1.408 at the end of 2009. From today's point of view, the proceeds of the capital increase in February 2011 have to be added to this liquidity.

Retrospection and outlook

The filing of the European drug approval for BF-200 ALA was Biofrontera's major operational focus in 2010. The required financial resources could be raised at the capital market. New share classes that were generated in capital increases in 2009, were combined with the old shares under a single ISIN in the regulated stock market. For the global sales of Belixos®, the cooperation in Arabic countries with Itrom Trading Drug Store, Dubai, was a first step.

The most important goal for 2011 is the European drug approval of BF-200 ALA and its market introduction in the first countries. Already in January 2011 the EMA has provided a positive assessment report. With the marketing approval of the first prescription drug, Biofrontera will mature to a less development and more marketing and sales driven organization.

http://bit.ly/gsJxfV

http://www.google.com/finance?q=ETR%3AB8F

japp. ich bleibe hier drin, breche mit der 30% regel.

die teutonen reden von 10 euro kursziel, das finde ich mehr als lächerlich. aber wenn bis zur zulassung oder einfach gesagt, in den nächsten 2 monaten, 5 euro drin sind, dann ist das ding super gelaufen.

sold for 2,88 EUR. (29,8%)

die gier darf nicht siegen! :oops:

sehe das ähnlich wie du. wenn der titel fällt kaufe ich nochmals ein. sobald volumen im spiel ist, wird das umso interessanter. im moment ist mir das einfach zu viel Poker. 8)

*hmpf*

3,515€ +0,315 €

+9,84 %

das wären schon über 50% gewinn... ik sterf! :cry:

Aurum wrote:

WARSICS wrote:

*hmpf*

3,515€ +0,315 €

+9,84 %

das wären schon über 50% gewinn... ik sterf! :cry:

Tja das hätte ich so auch nicht gedacht... Naja bis ins Q4 geht noch einen Moment... Nicht die erste Biotech welche hochgezockt wird

ich meinte es sei Q3 gewesen...

Biofrotera ist ein solides investment mit guten chancen auf höhere Preise.

kleine unterbewertete Firma...

Quote:

BF-200 ALA (European drug application filed) for actinic keratosis

Biofrontera’s lead product BF-200 ALA combines a nanoemulsion with 5-aminolevulinic acid (ALA). The product is developed in photodynamic therapy of precancerous skin lesions (actinic keratosis). The ALA nanoemulsion is applied to the skin lesions and, upon irradiation, a chemical reaction is triggered that destroys the affected skin without scar formation.

Phase II-studies for actinic keratosis, condyloma (genital warts) and basal cell carcinoma have been completed and demonstrated good efficacy and safety.

BF-200 ALA was tested in two pivotal phase III studies. The first placebo controlled phase III trial demonstrated excellent efficacy and safety. The second phase III trial compared BF-200 ALA with the registered standard medication in photodynamic therapy. The clinical development is now completed and the centralized European drug application was filed.

ok danke. werd mir nacher das interview mit dem CFO anhören.

10. Mai 2011 HV. geht jemand hin?

jemand hier noch dabei?

habe hier von der bank ein angebot für neue obligationen/warrants erhalten. Sonst noch wer?

werde leider aus dem ganzen nicht wirklich schlau?

kann jemand weiterhelfen?

Danke!

habe B8F nur noch auf watch ab und zu. war meiner meinung nach ein guter deal zu 2,20 dazumal - habe aber bei 2,90 und vor wochen alles abgestossen. waren die letzte woche nochmal günstig - aber mir zu risky, ehrlich gesagt.

obligation / warrant kommt für mich nicht in frage. weil ich keine ahnung davon habe.

arsenal wrote:

jemand hier noch dabei?

habe hier von der bank ein angebot für neue obligationen/warrants erhalten.

Danke!

ok cool...zu welchem Ausübungspreis werden dir die Warrants und Obligationen angeboten und in welchem Zeitrahmen kannst du diese ausüben?

gruess

so siehts aus...

:?: :!:

du kannst jetzt warrants kaufen die einen ausübungspreis von 3 euro haben und bis 2016 laufen. wenn die Aktie sagen wir im November 2011 bei 5 Euro steht, hast du das recht die Aktie für 3 Euro zu kaufen. hast dann also 2 Euro gewinn pro Aktie....

+8%

langsam wirds spannend....

volumen? oder immer noch kein rappeln in der kiste?

heute +12.50%

jemand dabei?

4,18€